Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Accumulated Expenses for 10 consecutive years, with $121.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 91.8% to $121.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.7 million through Dec 2025, up 91.8% year-over-year, with the annual reading at $121.7 million for FY2025, 91.8% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $121.7 million at Akebia Therapeutics, up from $106.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $144.7 million in Q3 2021, with the low at $51.1 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $86.0 million, with a median of $83.7 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses crashed 55.29% in 2023, then soared 103.81% in 2025.
  • Over 5 years, Accumulated Expenses stood at $109.0 million in 2021, then crashed by 30.49% to $75.8 million in 2022, then decreased by 10.61% to $67.7 million in 2023, then dropped by 6.31% to $63.5 million in 2024, then surged by 91.8% to $121.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $121.7 million, $106.4 million, and $91.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.